SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-22-025077
Filing Date
2022-11-14
Accepted
2022-11-14 17:22:50
Documents
63
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q harp-20220930.htm   iXBRL 10-Q 3494174
2 EX-31.1 harp-ex31_1.htm EX-31.1 15532
3 EX-31.2 harp-ex31_2.htm EX-31.2 15523
4 EX-32.1 harp-ex32_1.htm EX-32.1 13456
  Complete submission text file 0000950170-22-025077.txt   10526456

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT harp-20220930_pre.xml EX-101.PRE 299727
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT harp-20220930.xsd EX-101.SCH 49837
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT harp-20220930_lab.xml EX-101.LAB 408363
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT harp-20220930_def.xml EX-101.DEF 185813
9 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT harp-20220930_cal.xml EX-101.CAL 41701
57 EXTRACTED XBRL INSTANCE DOCUMENT harp-20220930_htm.xml XML 2119804
Mailing Address 131 OYSTER POINT BOULEVARD SUITE 300 SOUTH SAN FRANCISCO CA 94080
Business Address 131 OYSTER POINT BOULEVARD SUITE 300 SOUTH SAN FRANCISCO CA 94080 650-443-7400
Harpoon Therapeutics, Inc. (Filer) CIK: 0001708493 (see all company filings)

IRS No.: 473458693 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38800 | Film No.: 221387889
SIC: 2836 Biological Products, (No Diagnostic Substances)